CO68 Simulated mOS of Gemcitabine+Carboplatin ± Maintenance Avelumab Therapy or Enfortumab Vedotin + Pembrolizumab in First-Line Treatment of LA/mUC in Patients Ineligible for Cisplatin Using Disease Modeling
| Autor: | Galsky, M.D., Sonpavde, G.P., Bloudek, B., Farrar, M., Hepp, Z., Timmons, J., Powles, T. |
|---|---|
| Zdroj: | In Value in Health June 2023 26(6) Supplement:S26-S27 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect